Biodexa Pharmaceuticals Plc ADR (BDRX)

$2.83 -0.40 (-12.38%)
Market Cap 1.75M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.04
Volume 217,200
Avg Vol 1,158,726
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 0%
Beta 0.95
Analysts Strong Buy
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
TradeVoltage
TradeVoltage Dec. 26 at 3:22 PM
$AVAV $OMER $GS $BDRX $RCAT !!!
0 · Reply
prodoehlcameliaus
prodoehlcameliaus Dec. 26 at 3:07 PM
$LUNR $BBAI $PAAS $BDRX $PYPL
0 · Reply
tetzbilly626
tetzbilly626 Dec. 26 at 3:03 PM
$LUNR $BBAI $PAAS $BDRX $PYPL
0 · Reply
Bazzzigar
Bazzzigar Dec. 26 at 2:23 PM
$BDRX join with HIMS
0 · Reply
CoachHendo
CoachHendo Dec. 26 at 1:36 PM
$BDRX DT!
0 · Reply
MB755
MB755 Dec. 26 at 12:54 PM
$BDRX how many shares in the float?
1 · Reply
tetzbilly626
tetzbilly626 Dec. 26 at 12:49 PM
$XOM $BDRX $SOBR
0 · Reply
mz08
mz08 Dec. 26 at 11:27 AM
$BDRX 100 coming
0 · Reply
TradeVoltage
TradeVoltage Dec. 26 at 11:23 AM
$BDRX If you missed a runner, don’t get discouraged just add UPC to your watchlist. UPC has the potential to be the next big runner. Very low watchers on Stocktwits and hardly any attention so far. If you’ve ever wanted to catch something super early, this could be it
0 · Reply
mz08
mz08 Dec. 26 at 11:23 AM
$BDRX LFG 100
0 · Reply
Latest News on BDRX
Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 8 days ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 25 days ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 4 weeks ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 7 weeks ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 2 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 3 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 3 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 4 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 5 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 5 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 5 months ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 5 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 6 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 6 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 6 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 6 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 7 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 7 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 7 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 7 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 7 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 8 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 9 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 9 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 10 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 10 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 10 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 10 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 11 months ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 11 months ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 11 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 17, 2024, 7:30 AM EDT - 1 year ago

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

TradeVoltage
TradeVoltage Dec. 26 at 3:22 PM
$AVAV $OMER $GS $BDRX $RCAT !!!
0 · Reply
prodoehlcameliaus
prodoehlcameliaus Dec. 26 at 3:07 PM
$LUNR $BBAI $PAAS $BDRX $PYPL
0 · Reply
tetzbilly626
tetzbilly626 Dec. 26 at 3:03 PM
$LUNR $BBAI $PAAS $BDRX $PYPL
0 · Reply
Bazzzigar
Bazzzigar Dec. 26 at 2:23 PM
$BDRX join with HIMS
0 · Reply
CoachHendo
CoachHendo Dec. 26 at 1:36 PM
$BDRX DT!
0 · Reply
MB755
MB755 Dec. 26 at 12:54 PM
$BDRX how many shares in the float?
1 · Reply
tetzbilly626
tetzbilly626 Dec. 26 at 12:49 PM
$XOM $BDRX $SOBR
0 · Reply
mz08
mz08 Dec. 26 at 11:27 AM
$BDRX 100 coming
0 · Reply
TradeVoltage
TradeVoltage Dec. 26 at 11:23 AM
$BDRX If you missed a runner, don’t get discouraged just add UPC to your watchlist. UPC has the potential to be the next big runner. Very low watchers on Stocktwits and hardly any attention so far. If you’ve ever wanted to catch something super early, this could be it
0 · Reply
mz08
mz08 Dec. 26 at 11:23 AM
$BDRX LFG 100
0 · Reply
Candyman_Trader
Candyman_Trader Dec. 26 at 11:13 AM
Boxing Day FIRST WATCHLIST $SOAR $NCL $SIDU $BDRX $SPRC I’m thinking wee don’t have as many participants as usual, doubtful companies come out with very bullish news today, discipline and selectivity will be very important today. Play safe and have a plan! Im going LIVE in a few minutes https://youtube.com/@candyman.trader?si=5bKmLFjkEBaKCoG7
0 · Reply
GATTACA2025
GATTACA2025 Dec. 26 at 10:05 AM
$BDRX $TAOP shorting both. You can try to squeeze me.
0 · Reply
GATTACA2025
GATTACA2025 Dec. 26 at 10:00 AM
$BDRX buying at 2
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 24 at 5:32 PM
$SLS NEED TO HANDLE BEUD $BDRX
1 · Reply
Love_To_Learn
Love_To_Learn Dec. 24 at 1:07 PM
$BDRX gave u tracks ok dont b grumpy
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 24 at 1:07 PM
$BDRX brought u a party of all annoying people beud this morning all of them annoying
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 24 at 12:33 PM
$TNMG 3.23/3.24 me 3.24 anomaly fo markets and introducing u correctly to BEUD $BDRX back n forth with $INDP and i know beud its been an annoying morning for u people screaming all morning
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 24 at 11:49 AM
$BDRX brought u a guest this morning beud they r annoying INDP
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 23 at 1:32 PM
$BDRX fusing beud with the anomaly
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 23 at 1:31 PM
$BDRX accessing 3.24 anomaly
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 22 at 9:57 PM
$BDRX UPDATE PENDING WONT B ORGANIC
1 · Reply
Love_To_Learn
Love_To_Learn Dec. 22 at 9:56 PM
$BDRX PUT U IN A BIG CORNER MY BEUD DUE TO SLS AND FEW OTHER THINGS CREATING FRESH TRACKS FOR U
0 · Reply